Title![]() |
Intervention | NCT ID | Sponsor | Status |
---|---|---|---|---|
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful... | Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration | NCT02521285 | National Cancer Institute (NCI) | Active, not recruiting |
Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma | Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration | NCT02965703 | National Cancer Institute (NCI) | Active, not recruiting |
An Internet-based Program to Help Cancer Survivors Manage Pain | Internet-based pain coping skills program | NCT04462302 | Wake Forest University Health Sciences | Recruiting |
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II... | Exemestane, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery | NCT02598557 | National Cancer Institute (NCI) | Active, not recruiting |
Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast | Afimoxifene, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration | NCT03063619 | M.D. Anderson Cancer Center | Active, not recruiting |
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer... | Best Practice, Educational Intervention, Motivational Interviewing, Quality-of-Life Assessment, Questionnaire Administration, Text Message-based Navigation Intervention | NCT04379570 | Alliance for Clinical Trials in Oncology | Recruiting |
Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts | Contrast-enhanced Magnetic Resonance Imaging, Digital Tomosynthesis Mammography, Quality-of-Life Assessment, Questionnaire Administration | NCT02933489 | ECOG-ACRIN Cancer Research Group | Active, not recruiting |
Why I Joined a Clinical Trial
I was the first patient who Dr. Abraham enrolled on the NSABP B-31 clinical trial (chemo vs chemo + Trastuzumab in HER-2 positive breast cancer). I am grateful to him for presenting me with the opportunity to join the study 20 years ago in March 2001 and that I had the courage to participate, as I continue to do well to this day. This clinical trial ended up changing the landscape of treatment for future patients with breast cancer.